TIDMSNG

RNS Number : 8673Q

Synairgen plc

30 June 2022

Synairgen plc

('Synairgen' or the 'Company')

Results of Annual General Meeting

Southampton, UK - 30 June 2022: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, announces the results of voting at its Annual General Meeting today. All resolutions proposed at its Annual General Meeting were passed.

Resolutions 12 (to authorise the directors to allot shares) and 13 (to disapply pre-emption rights) were withdrawn from the agenda following discussions with a small number of shareholders.

The full results of the proxy voting and text of the resolutions can be viewed by visiting the Company's website at www.Synairgen.com.

For further enquiries, please contact:

Synairgen plc

Brooke Clarke, Head of Communications

Media@synairgen.com

Tel: + 44 (0) 23 8051 2800

finnCap (NOMAD and Joint Broker)

Geoff Nash, Kate Bannatyne, Charlie Beeson (Corporate Finance)

Alice Lane, Sunil de Silva (ECM)

Tel: + 44 (0) 20 7220 0500

Numis Securities Limited (Joint Broker)

James Black, Freddie Barnfield, Duncan Monteith

Tel: + 44 (0) 20 7260 1000

Consilium Strategic Communications (Financial Media and Investor Relations)

Mary-Jane Elliott, Namrata Taak, Lucy Featherstone

cscsynairgen@consilium-comms.com

Tel: +44 (0) 20 3709 5700

MKC STRATEGIES, LLC (US Media Relations)

Mary Conway

MConway@MKCStrategies.com

Tel: +1 516-606-6545

Notes for Editors

About Synairgen

Synairgen is a UK-based respiratory company focused on drug discovery, development and commercialisation. The Company's primary focus is developing SNG001 (inhaled interferon beta) for the treatment of severe viral lung infections, including COVID-19, as potentially the first host-targeted, broad-spectrum antiviral treatment delivered directly into the lungs. SNG001 has been granted Fast Track status from the US Food and Drug Administration (FDA). Founded by University of Southampton Professors Sir Stephen Holgate, Donna Davies and Ratko Djukanovic in 2003, Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see www.synairgen.com .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGBDGDLBSXDGDG

(END) Dow Jones Newswires

June 30, 2022 08:45 ET (12:45 GMT)

Synairgen (LSE:SNG)
Gráfica de Acción Histórica
De Nov 2023 a Dic 2023 Haga Click aquí para más Gráficas Synairgen.
Synairgen (LSE:SNG)
Gráfica de Acción Histórica
De Dic 2022 a Dic 2023 Haga Click aquí para más Gráficas Synairgen.